ADA

Adenosine deaminase (ADA; EC 3.5.4.4) is a ubiquitous enzyme that catabolizes adenosine and deoxyadenosine to inosine and deoxyinosine. During an ischemic brain event, the extracellular adenosine concentration increases over 10-fold and adenosine is deaminated to inosine by ADA. Congenital ADA deficiency results in severe combined immunodeficiency (SCID), caused by an increase in deoxy-adenosine levels in the serum and tissues. This increases deoxy-ATP levels in the T-cells and causes T-cell apoptosis, and primarily affects lymphocyte development, viability, and function when diagnosed in infancy[1].


[1] R. Tamura et al. Neuroprotective effects of adenosine deaminase in the striatum. J Cereb Blood Flow Metab. 2016 Jan 8.

1 Item(s)

per page
Axon ID Name Description From price
2434 Deazaadenosine, 1- Adenosine deaminase (ADA) inhibitor with cytostatic activity in vitro €135.00

1 Item(s)

per page
Please wait...